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Abstract: Plant-based platforms have been successfully applied for the last two  
decades for the efficient production of pharmaceutical proteins. The number of 
commercialized products biomanufactured in plants is, however, rather discouraging. 
Cytokines are small glycosylated polypeptides used in the treatment of cancer, immune 
disorders and various other related diseases. Because the clinical use of cytokines is limited 
by high production costs they are good candidates for plant-made pharmaceuticals. Several 
research groups explored the possibilities of cost-effective production of animal cytokines 
in plant systems. This review summarizes recent advances in this field. 
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1. Introduction 
Development of DNA recombination and plant transformation techniques resulted in creating the 
novel protein production platforms based on either whole plants or plant cells. The results of the first 
experiments describing the plant-based production of pharmaceutical proteins were published about 
25 years ago. The successful production of the human growth hormone in tobacco and sunflower [1] 
and of albumin in tobacco and potato [2] indicated that plant-based production systems might be used 
for the production of mammalian proteins. The process of using plant-based systems as highly 
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effective production platforms for the molecules with biotechnological (industrial or pharmaceutical) 
significance is named molecular farming, while the pharmaceutical products obtained in the  
plant-based systems are often called plant-made pharmaceuticals (PMPs). At present, a list of PMPs in 
various stages of development or potential commercialization is quite extensive and includes various 
antibodies and their fragments, vaccine antigens, blood substitutes, enzymes, cytokines and other 
important and valuable proteins. Multiple examples of such proteins and the extensive evaluation of 
the advantages and disadvantages of various plant-based platforms for the expression of the particular 
targets can be found in many recent reviews (for example, [3], see also below), therefore this work is 
limited only to a small group of PMPs, the cytokines. 
2. Cytokines and Their Therapeutic Application 
Cytokines are small polypeptides, proteins or glycoproteins involved in the regulation of processes 
as diverse as proliferation, differentiation and mobility of cells. Cytokines are important components of 
the immune system; however they also participate in embryogenesis, affect the hematopoietic system 
and act on neuronal cells. The anatomic and structural distinctions between hormones and cytokines 
are unclear and cytokines are sometimes named the hormones of immune system. They can have an 
affect not only on cells in the close proximity but also those in distant organs. Cytokines  
are characterized by a considerable complexity of actions such as redundancy, pleiotropy, 
multifunctionality, synergistic or antagonistic effects and cascades of positive or negative feedbacks. 
At present, more than 100 different cytokines are known. Several methods of division of this large 
family into subgroups have been used. The most convenient seems to be functional categorization 
according to KEGG (Koto Encyclopedia of Genes and Genomes [4]). As shown in Figure 1, at least 
8 families can be distinguished: Class I cytokines (hematopoietin family), Class II cytokines 
(interferons/IL-10 family), platelet-derived growth factors (PDGF), tumor necrosis factors (TNF 
family), IL-1 family, IL-17 family, tumor growth factor family (TGF-beta family) and chemokines. 
For more information about the cytokines the reader is referred to the Cytokines & Cells Online 
Pathfinder Encyclopedia (COPE) [5]. 
An imbalance in cytokine production or signaling contributes to various pathological immune and 
inflammatory disorders. In addition, plasma levels of various cytokines may give information on the 
presence, or even predictive value of inflammatory processes involved in autoimmune diseases such as 
rheumatoid arthritis. The biological role of cytokines and their dual (immunosuppressive as well as 
immunostimulatory) properties are a strong indication for multiple clinical applications. A number of 
recombinant cytokines have been approved for clinical use (Table 1) and multiple cytokine therapies 
are in clinical trials [6–8]. Not only the cytokines but also cytokine receptors, antagonists of the 
cytokine receptors and the relevant specific antibodies can be used in therapy [8]. Significant numbers 
of cytokines have been tested as potential adjuvants of immunological response, particularly during 
mucosal immunizations, such as oral, intranasal and intravaginal [2,9]. Granulocyte-macrophage 
colony stimulating factor (GM-CSF) seems to e one of the best candidates for PMP because it is 
relatively stable, consists of one kind of polypeptide, i.e., it is encoded by one gene, and, essentially, it 
is well tolerated by the patients. Numerous new implications of this cytokine have been proposed and 
tested in preclinical and clinical trials, including the combined application of GM-CSF and IL-2 as 
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adjuvants in cutaneous melanoma along with autologous vaccine [10]. However, it is necessary to 
mention that the use of cytokines as adjuvants in vaccines is considered controversial because they can 
sometimes have serious side effects such as vascular leak syndrome [11]. An interesting idea is the 
production and application of ―fusokines‖, hybrid molecules generated after cloning and fusing two 
separate cytokine encoding cDNAs into a single open reading frame, however these experiments have 
been limited to the murine experimental models [12]. 
Figure 1. The families of cytokines (according to the Kyoto Encyclopedia of Genes and 
Genomes [4]). 
 
Table 1. Examples of cytokines approved for use in humans. Modified from [7,8]. 
Cytokine  Disease or Indication Drug Name (Company) 
G-CSF Neutropenia Neupogen/Filgrastim (Hoffmann-La Roche) 
GM-CSF 
Leukemia 
Bone marrow 
Stem cell transplants 
Leukine/Sargramostin (Bayer) 
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Table 1. Cont. 
Cytokine  Disease or Indication Drug Name (Company) 
Interferon-α (INF-α) 
Chronic hepatitis B 
Chronic hepatitis C 
Hairy cell leukemia 
Chronic myeloid leukemia 
Condyloma acuminate 
AIDS-related Kaposi’s sarcoma 
genital warts 
Intron A (Schering Plough) 
Roferon A (Hoffman La Roche) 
Infergen (Three Rivers Pharmaceuticals) 
Alferon N (HEMISPHERx Biopharma) 
Pegasys (Genentech USA/Roche) 
Pegintron (Merck) 
Interferon-β (INF-β) Relapsing multiple sclerosis 
Betaseron (Bayer) 
Avonex (Biogen Idec) 
Interferon-γ (INF-γ) 
Malignant osteopetrosis 
Chronic granulomatous disease  
Actimmune (Intermune Pharma) 
Erythropoietin-α 
(EPO-α) 
Anemia due to chronic renal failure 
HIV infected patients 
Chemotherapy 
Primary bone marrow disorders 
Eprex (Cilag Jansen) 
Epogen (Amgen) 
Procrit (Ortho Biotech) 
IL-2 
Metastatic renal cell cancer 
Metastatic melanoma 
Aldesleukin (Novartis) 
Proleukin (Prometheus Laboratories) 
IL-11 Thrombocytopenia 
Oprelvekin/Neumega (Genetics Institute, Inc./ 
Wyeth/Pfizer)  
3. Recombinant Cytokines from Plant-Based Platforms 
Plant-based production of recombinant cytokines is an emerging area and most previous research 
has concentrated on a few well-characterized cytokines. Some most interesting examples from the list 
shown in Table 2 are briefly discussed below. 
3.1. Hematopoietin Family 
Erythropoietin was one of the first cytokines produced in plant cells [13]. The cDNA encoding 
human erythropoietin was expressed from the 35S promoter of cauliflower mosaic virus (CaMV) in 
the tobacco BY2 cells. The signal peptide at the N-terminus was intended to enable the extracellular 
secretion of the recombinant protein. The secretion was observed in the protoplasts cultures, while in 
the cell cultures erythropoietin was translocated though the cellular membrane but it stayed bound by 
the cell wall and was not secreted into the medium. Most probably, the size of 30 kDa was too large 
for free migration through the cell wall. The protein is glycosylated in animal cells, so was examined 
in plant cells, however the pattern and length of the sugar chain were different. Unfortunately, only a 
low yield (0.0026% of total soluble protein [TSP]) was achieved. The protein was biologically active 
in vitro but not in vivo. The possible explanation for this might be the difference in glycosylation, 
which is known to affect the protein stability in blood.  
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Table 2. Examples of cytokines produced in plant-based systems. Different expression systems are marked differently (no  
background-suspension cultures; light grey-transgenic or transplastomic plants; dark grey-plant virus-based production); nos-nopaline 
transcriptional terminator, MUbi-1 i Scubi-9-polyubiquitin promoters; * Method of transformation: T-Agrobacterium-mediated;  
M-microbombardment, V-viral vector, L-lipofectin-mediated transformation of protoplasts. The examples concern human cytokines unless 
indicated otherwise. 
Cytokine * Method/Plant Material Selected Elements of the Expression Cassette Expression Level/Yield Reference 
erythropoietin T/tobacco (BY2) cells 
suspension  
35S promoter and terminator 0.0026% TSP; 25 pg/L [13] 
G-CSF  T/tobacco cells suspension  35S promoter with the double enhancer, Ω-translation enhancer; 
nos terminator 
105 μg/L [14] 
GM-CSF T/tobacco cells suspension  35S promoter, translation enhancer from TEV, His tag,  
T7 terminator 
150 µg/L (intercellular); 250 µg/L 
(secretory)  
[15] 
GM-CSF  T/tobacco cells suspension  35S promoter with the double enhancer, nos terminator 180–780 µg/L [16] 
GM-CSF  M/rice cells suspension  rice amylase promoter and signal peptide 129 mg/L 
(25% secreted proteins)  
[17] 
GM-CSF M/rice cells suspension rice amylase promoter and signal peptide, RNAi-mediated 
silencing of α-amylase gene to 8.2% 
280 mg/L [18] 
GM-CSF M/rice cells suspension  rice amylase promoter and signal peptide, RNAi-mediated 
silencing of cysteine proteinase 
290 mg/L [19] 
GM-CSF M/rice cells suspension rice amylase promoter and signal peptide; co-expression  
of gene encoding synthetic protease inhibitor (SPI-II) 
250 mg/L [20] 
GM-CSF M/sugarcane leaves  MUbi-1 promoter from maize or SCubi-9 from sugarcane 0.02% TSP [21] 
GM-CSF  T/tobacco seeds Gt1, Gt3 (glutelin) promoters and signal peptide,  
nos terminator 
0.005–0.03% TSP 
 
[22] 
GM-CSF T/tobacco seeds Gt1 (glutelin) promoter and signal peptide, nos terminator 1.3% TSP [23] 
GM-CSF T/rice seeds Gt13a (glutelin) promoter (specific for seed endosperm) and 
glutelin signal peptide, nos terminator, codon optimalization 
0.5–14 μg/seed [24] 
Murine GM-CSF T/tobacco leaves RbcS1 Promoter; signal peptide, KDEL 19 µg/g fresh leaves; 0.22% [25] 
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Table 2. Cont. 
Cytokine * Method/Plant Material Selected Elements of the Expression Cassette Expression Level/Yield Reference 
GM-CSF  V/N. benthamiana leaves PVX-derived vector: 35S promoter, His tag 0.2–2% TSP [26] 
IL-2  T/tobacco cells suspension  35S promoter, T7 terminator 0.09 mg/L [27] 
IL-2 T/potato tubers  patatin promoter; nos terminator 115 U/mg TSP [28] 
Murine IL-2 T/Arabidopsis seeds 
T/tobacco seeds 
novel binary Gateway vector (pPphasGW) containing  
β-phaseolin promoter from common bean and the signal peptide 
of the Arabidopsis 2S2 seed storage protein gene; KDEL 
Much higher yield in Arabidopsis 
than in tobacco: 0.3 mg/g of seeds 
(0.7% TSP); biologically active  
in vitro 
[29] 
IL-4 T/tobacco leaves  35S promoter with double enhancer, t-CUP-translation 
enhancer, ELP, KDEL, nos terminator  
0.086% TSP [30] 
IL-4 T/tobacco leaves,  
T/potato tubers  
35S promoter, KDEL sequence 0.1% TSP in tobacco;  
0.08% TSP in potato 
[31] 
IL-4 T/tobacco cells suspension  35S CaMV promoter, T7 terminator 0.45 mg/L [27] 
IL-10  T/tobacco leaves  35S promoter with double enhancer, t-CUP-translation 
enhancer, ELP, KDEL, nos terminator 
0.27% TSP [30] 
IL-10 T/tobacco leaves  (A) promoter 35S CaMV, with or without His tag,  
chloroplast leader peptide 
(B) promotor 35S CaMV, His tag; mitochondria  
leader peptide 
(A) 7 ng/mg TSP (without His);  
43 ng/mg TSP (with His) 
(B) no accumulation 
[32] 
IL-10 T/rice seeds  GluB-1 promoter and signal peptide, His tag, KDEL, 
codon optimization 
2 mg of pure IL-10 per 40 g  
of rice powder 
[33] 
IL-10 T/tobacco leaves 35S promoter with double enhancer; three constructs for each 
viral IL-10 or murine IL-10, ER-targeted, plasma membrane 
(IL-10 facing the apoplast), ER-membrane (IL-10 facing the 
cytosol) assayed in transient expression system, cassettes for 
ER-targeted cytokines were used for the stable expression 
Viral: 10.8 µg/g fresh leaves 
Murine: 37.0 µg/g fresh leaves 
[34] 
IL-12 T/tobacco leaves  35S promoter and terminator 40 ng/g [35] 
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Table 2. Cont. 
Cytokine * Method/Plant Material Selected Elements of the Expression Cassette Expression Level/Yield Reference 
IL-12 T/tomato leaves and fruits  35S promoter with double enhancer; 35S terminator 7.3 μg/g leaves 
4.3 μg/g fruits 
[36,37] 
IL-12 T/tobacco cells suspension  35S promoter with double enhancer; Ω-translation enhancer 175 μg/L [38] 
IL-13 T/tobacco leaves  double 35S promoter; translation enhancer from AMV; KDEL; 
nos terminator 
0.15% TSP [39] 
IL-18 T/tobacco leaves  35S promoter with double enhancer, Ω-translation enhancer, 
nos terminator 
0.004–0.051% TSP; 351 ng/g [40] 
cardiotrophin-1 M/tobacco leaves, chloroplasts 
transformation 
(A) promotor rrn (promoter 16S RNA), translation enhancer 
(5’UTR/leader sequence of the phage T7 gene 10) 
(B) psbA promoter and translation enhancer (5’UTR psbA) 
(A) 0.14 mg/g leaves 
(B) up to 1.14 mg/g leaves  
[41] 
IFN-α2b  
IFN-α8 
T/potato - 560 IU/g of tissue [42] 
IFNα L/tomato (leaf tissue and  
cells suspension) 
P1 portion of the dual ―bi-directional‖ promoter from 
A. tumefaciens cDNA, polyadenylation signal from 
A. tumefaciens gene-7 
923–3029 U/g FW tissue [43] 
IFN-α2 V/squash (Cucurbita pepo) and 
cucumber (Cucumis sativus) 
Viral vector dirived from attenuated zucchini yellow mosaic 
potyvirus (AG) 
max. 430,000 IU/FW of leaves [44] 
IFN-α2b M/tobacco leaves, chloroplasts 
transformation 
Cassette: 5’UTR/HIS/THR/IFNα2b cloned into the chloroplast 
vector pLD-CtV 
3 mg/g, 20% TSP [45] 
IFN-α2b  T/carrot leaves (A) 35S promoter, nos terminator, calreticulin apoplast  
targeting signal  
(B) taproot-specific Mll promoter, nos terminator, calreticulin 
apoplast targeting signal 
Biological activity on average:  
(A) 26.8 × 103 U/g FW of young 
leaves 
(B) 8.56 × 103 U/g FW of roots 
[46] 
IFNβ transient, agroinfiltration of the 
leaves of lettuce 
35S promoter, nos terminator 3.1 × 104 IU/mL [47] 
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Table 2. Cont. 
Cytokine * Method/Plant Material Selected Elements of the Expression Cassette Expression Level/Yield Reference 
IFNγ T/rice cells suspension (A) constitutive maize ubiquitin promoter, with or without 
αAmy3 leader peptide; His tag;  
(B) sucrose-starvation inducible promoter (rice αAmy3 
promoter); with or without αAmy3 leader peptide; His tag 
(A) 11.1 ng/mL (secretory) and 
699.79 ng/g cell (intracellular) 
(B) 17.4 ng/mL media (secretory) 
and 131.6 ng/g cell (intracellular) 
[48] 
Chicken IFN-α Transient expression, 
agroinfiltration of the  
leaves of lettuce 
35S promoter, nos terminator 0.393 μg/kg tissue, 0.0004% TSP [49] 
Fish IFN- α1 T/rice 
T/potato 
35S promoter with double enhancer, nos terminator 
 
Biological activity: 
in rice-up to 0.82 U/mg leaves; 
in potato-up to 5.4 U/mg leaves 
[50] 
TNF-α  
 
T/potato 35S promoter, Ω-translation enhancer, SEKDEL sequence 15 µg/g tissue [51] 
Fibroblast growth 
factor 8 isoform b 
(FGF8b) 
T/tobacco leaves 35S promoter with double enhancer; 35S terminator ,c-myc, 
His, KDEL 
4.1% TSP [52] 
Insulin like growth 
factor 1 (IGF-1) 
M/tobacco, transplastomic psbA promoter, translantion enhancer (5’UTR psbA)  
and ZZ-tag from S. aureus, codon optimization 
up to 32% TSP [53] 
Insulin like growth 
factor 1 (IGF-1) 
M/rice seeds Glutelin (Gt13a) promoter, the Gt13a signal peptide in  
frame with the fusion protein containing IGF-1 attached  
to the C-terminus of ER luminal binding protein (BipC) ,  
nos terminator 
up to 6.8% of total seed protein; 
biologically active in vivo 
(effectively reduced blood glucose 
in diabetic mice) 
[54] 
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Several independent groups focus on the production of human GM-CSF. Initially, it was produced 
in tobacco [15,16] and rice [17–20] cell suspension cultures. One of the most interesting approaches to 
improve the yield was the addition of either mineral salts or BSA to the growth medium, which 
stabilized the secreted cytokine [15]. A significant (up to 4-fold) increase of the yield was achieved 
due to the addition of 5% (w/v) gelatin to the medium [16]. However, in cultures older than 4 days, 
gelatin inhibited cell growth, presumably by activation of proteolytic enzymes. Much higher efficiency 
was achieved in cultures of rice cell suspension, particularly with the specific promoter of rice 
amylase, Ramy3D [17]. Using this system, a yield of 129 mg/L of culture was achieved in the absence 
of sugar (when this promoter is activated). The system was subsequently optimized in three strategies:  
(i) silencing of the gene encoding a-amylase, a dominant protein secreted by rice cells [18]; 
(ii) silencing of the gene encoding cysteine proteinase secreted by the rice cells to the medium [19]; 
and (iii) co-expression of cytokine with the protease inhibitor [20]. Each of these strategies increased 
the yield of recombinant GM-CSF at least two-fold.  
Whole plant platforms were also used for GM-CSF production. The maximal yield in the leaves of 
transgenic sugarcane was about 0.02% [21] and in tobacco leaves about 0.22% of TSP [25]. In the 
seeds of transgenic rice recombinant GM-CSF accumulated up to 1.3% of TSP [23]. The highest 
expression (up to 2% TSP) was reported for the viral vector based on PVX (potato virus X) with 
modified coat protein [26]. In most cases the biological activity of recombinant GM-CSF was 
confirmed in vitro, while in at least in one case it was also verified in vivo in a mouse model [24]. 
The first report about the expression of recombinant IL-2 and IL-4 in tobacco cell suspension 
cultures was published in 1998 [27]. The authors assumed that the presence of intrinsic signal peptide 
would provide an efficient extracellular secretion of recombinant proteins. In fact, most of the cytokine 
produced was retained in the cells and only the secreted proteins had biological activity. Other 
strategies include targeting of the recombinant IL-4 proteins into endoplasmic reticulum, using the 
promoter specific to potato tubers or expression as a protein fusion with elastin, however the reported 
yield was never higher than 0.08% for IL-4 [30] or 115 U/g of potato tuber for IL-2 [28]. 
Other examples of cytokines from this group produced in plant-based platforms include 
cardiotrophin 1 [41], interleukin 12 [35–38], interleukin 13 [39] and interleukin 18 [40]. Interestingly, 
IL-12 was produced as a multimeric protein at levels exceeding 5% of TSP after coinfiltration of 
Nicotiana benthamiana leaves with two Agrobacterium strains individually encoding each subunit [55]. 
Cardiotrophin 1 was produced in transplastomic tobacco plants with an efficiency of about 5%. In 
addition, it appeared that its biological activity is inhibited by light, which most probably destroys the 
protein conformation [41]. 
3.2. Interferon and IL-10 Family 
Interferons have been frequently selected as candidates for production in plant-based systems. The 
first reports about the plan-based production of human interferon date back to the beginning of the  
90 s [56], however it was the usage of transplanstomic plants that allowed for the huge increase of 
yield, up to 20% of TSP [45]. It is worth mentioning that not only human interferons but also 
interferons from chicken [49] and salmon [50] were successfully produced in plant-based systems. 
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In plant-based systems, interleukin 10 was targeted either to chloroplasts or mitochondria, with 
better results for the former organelle [32]. In the case of this cytokine, the best yield of 0.27% TSP 
was achieved after expression of IL-10 in fusion with elastin [30]. 
3.3. Other Families 
The single representatives of the other families of cytokine were produced in plant systems 
(Table 2). 
Tumor necrosis factor (TNF-α), which is a member of the TNF family, has been produced in  
potatoes [51]. The authors used two types of expression cassettes, both containing 35S promoter of 
CaMV and the translation enhancer from TMV. One of the cassettes had additional sequences 
encoding the N-terminal signal peptide and the C-terminal SEQDEL peptide, responsible for ER 
targeting. However, this strategy did not result in any significant increase of cytokine accumulation.  
In both cases the yield was similar and reached about 15 µg of biologically active TNF-α per 1 g of  
plant tissue. 
Interleukin 18 belongs to the IL-1 family. In this case, the enhanced 35S promoter and the 
translation enhancer from TMV were used; however the yield was moderate, up to 0.05% of TSP [40]. 
Bioactive human fibroblast growth factor 8b (FGF), a member of PDGF family, was produced in 
tobacco plants [52]. The cDNA coding hFGF8b was cloned under control of the double CaMV 35S 
promoter (CaMV35SS). In an Agrobacterium-mediated transient expression system after vacuum 
leaves infiltration the yield of the Ni-NTA affinity chromatography purified proteins c-myc-His tagged 
FGF8b and His-KDEL tagged FGF8b was 2.7% and 4.1% of TSP (90 and 150 µg/g FW), respectively. 
Another member of the same PDGF family, Insulin-like Growth Factor 1 (IGF-1), was efficiently 
produced in transplastomic plants [53]. Cell proliferation assays in human HU-3 cells demonstrated the 
biological activity of this recombinant protein. 
4. Prospects for Commercialization Plant-Produced Cytokines 
The successful introduction of plant-produced recombinant cytokines into the market might 
encounter problems similar to those encountered in the commercialization of any other PMPs [57]. 
These problems can be divided into two main categories: (i) technological (such as low yield, poor 
performance of the recombinant product or problems with postharvest bioprocessing) making the 
platforms economically uncompetitive and (ii) legal (such as public objections and stringent regulatory 
requirements for open-field cultivation of transgenic plants, high regulatory-approval costs and long 
timelines), which result in a long timeframe-to-market and a lack of interest from the potential investors.  
4.1. Strategies Used to Improve the Performance of Plant-Base Production Platforms 
The researchers dealing with molecular farming issues have always been aware of the needs for 
technological improvement. Various factors limit the yield of PMPs and there are multiple possibilities 
to overcome the yield and economic constrains. These problems have been frequently considered in 
many excellent reviews [58–60]. The concerns generally expressed with regard to PMPs also pertain to 
the plant-produced cytokines. Therefore, we would like to mention briefly only a few strategies, which 
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were successfully applied in the case of this type of therapeutics. First of all, some PMPs can be 
produced in edible crops to eliminate the need for purification of the desired products in the case of 
oral application of the recombinant proteins. In addition, several critical elements must be optimized to 
get a high yield of PMP, including the use of tissue specific promoter or optimization of the codons 
within the transgene to match the optimal codons of the host. For example, efficient accumulation 
Insulin-like Growth Factor I (IGF) was achieved in transgenic tobacco chloroplasts after codon 
optimization of the transgene [34,53]. The native IGF gene (IGF-n) with less than optimal for 
chloroplast AT content of 41% or synthetic (IGF-s) gene with optimized 60% AT were cloned into a 
vector containing the psbA promoter, 5’UTR (which enhances translation under illumination) and 
3’UTR (which increases the stability of the transcript). The IGF-n transgenic plants had an expression 
level of 9.5% TSP. In IGF-s plants, expression level increased to 11.3% TSP, however the expression 
of IGF was increased up to 32% TSP under continuous illumination by the chloroplast light regulatory 
elements. The importance of protein stability is illustrated by other reported cases, where significant 
elevation of the yield was achieved by targeting the PMP into the storage organs such as seeds or 
grains [22–24,33]. For example, a strong endosperm-specific promoter (Gt13a) and rice-preferred 
codons optimization improved the transcription and translation of hGM-CSF, giving the yield of 
14 µg/seed [24]. In this case also a signal peptide that targeted recombinant protein into the 
endomembrane system of rice endosperm such as the ER and protein bodies was used to protect 
against degradation by proteases. Additionally, it is worth mentioning that accumulation in seeds might 
eliminate the need for low temperature maintenance during transport and long-term storage of PMPs. 
There are also successful examples of fusion strategies being used to obtain the high yield of 
recombinant cytokines in plants, including IGF-1 produced in fusion with the C-terminus of a rice 
luminal binding protein [54]. The appropriately designed fusion, which does not interfere with the 
biological activity of the recombinant proteins, might be a safe and effective oral delivery system for 
cytokins in general.  
Proteomic analysis of the effects of massive over-accumulation of GM-CSF in plants gave us some 
information about the fate of recombinant proteins in plant cells [61]. This work also indicated that the 
presence of recombinant protein might affect the total proteome of grain cells. For example, the major 
endogenous storage proteins, glutelin, globulin and prolamin, and a majority of carbohydrate-related 
proteins were down-regulated, while 26S proteasome-related proteins and molecular chaperons were 
up-regulated in transgenic rice endosperm. The author concluded that over expression of recombinant 
proteins induced unfolded protein response and that overall protein trafficking in rice endosperm was 
affected. This work shows that the influence of transgene expression on host metabolism is an 
important issue. 
4.2. Other Problems to Consider 
The initial pictures describing the feasibility of the production of edible plant-made pharmaceuticals 
or vaccines in carrots or bananas appeared somewhat naive. A direct consumption (oral application) of 
plant parts containing recombinant therapeutics might be controversial because of the need to meet the 
existing rigorous regulations concerning consistent composition of medicines for humans. Most legal 
and regulatory issues linked to the commercialization of PMPs were extensively discussed in a number 
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of recent reviews [57,62,63] and they will not be repeated here. There are also other problems and 
questions regarding the use of genetically modified plants and their effects on the human health and 
the environment in general. These issues include some concerns regarding ethics, related to the risk of 
transferring transgene (especially antibiotic-resistance markers) from genetically modified plants to the 
environment, gut microflora and pathogenic microbes. As mentioned earlier, the risk of uncontrolled 
spreading of the transgene can be substantially reduced by the strategy of biocontainment or physical 
containment. In addition, using marker-free technology eliminates the risk of transfer of the marker 
genes [64,65]. There are also some religious issues related to the consumption of transgenic plants with 
animal genes introduced into them, especially, for some strict vegetarian people and some ethnical 
groups with certain food preferences and restrictions, but this concern is outside the scope of the 
present review. 
It is necessary to mention that the avoidance of plant cultivation in open areas, applying various 
approaches of containment use and the usage of only isolated (purified) recombinant products lead,  
of course, to more expensive products and limit the direct use of GM plants as edible sources of 
recombinant therapeutics.  
5. Conclusions 
Recent development of knowledge about the immune system opens new perspectives for  
the application of cytokines and opens a potentially large market, however finding the niche for  
plant-produced recombinant cytokines in the pharmaceutical market might be tough. Many technical 
and regulatory challenges limit the availability of this sector for the prospective investors. All 
molecular farming projects, including those involved in the production of therapeutics for the 
treatment of immune system disorders, must consider the costs and feasibility of standardization, 
validation and licensing of the potential medical products. The biopharming industry is in a dynamic 
state and many companies involved in plant-based biomanufacturing of recombinant proteins cease to 
exist before the commercialization of any products [57]. Nevertheless, there are now about 20 PMPs, 
including at least one cytokine (interferon α) in development as potential products for the 
pharmaceutical market [66]. 
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